Date: For Release: Immediately Refer to: (317) 433-8990 Marni Lemons (317) 276-3570 Jeff Newton Lilly Expresses Concerns With Opinion of ADA...
Date: January 21 , 2004 For Release: Immediately Refer to: 317-433-9899 - Edward Sagebiel 317-277-1302 - Rob Smith Lilly Unveils Participation...
Date: January 15, 2004 For Release: Immediately Refer to: Marni Lemons 317-433-8990 FDA Approves Zyprexa?for Maintenance of Bipolar Disorder...
Date: January 12, 2004 For Release: Immediately Refer to: (317) 433-5058 - Karin Ricketts Lilly Launches Third Venture Capital Fund Lilly MedTech...
Date: January 7, 2004 For Release: Immediately Refer to: (317) 276-5795 - Terra L. Fox Lilly Sets Date and Conference Call for Fourth-Quarter and...
Lilly Announces 2004 Financial Guidance INDIANAPOLIS, Jan. 5 -- Eli Lilly and Company (NYSE: LLY) today announced its financial expectations for...
Eli Lilly and Company Eli Lilly and Company (NYSE:LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Symbyax(TM...
Eli Lilly and Company Eli Lilly and Company (NYSE:LLY) will announce its financial expectations for the first quarter and full year 2004 on...
Eli Lilly and Company According to parents involved in a new survey, attention-deficit/hyperactivity disorder (ADHD) doesn't start and end with...
Eli Lilly and Company Lilly Announces Dividend Increase The board of directors of Eli Lilly and Company (NYSE:LLY) today announced a 6 percent...
Eli Lilly and Company Rosemarie Kelly, 317-433-0150 Eli Lilly and Company (NYSE:LLY) today announces the addition of more robust content and a...
Eli Lilly and Company Terra L. Fox, 317-276-5795 Eli Lilly and Company (NYSE:LLY) will be hosting a meeting with pharmaceutical sell-side...
Eli Lilly and Company Carole Copeland (media), 317-277-3661 or ICOS Lacy Fitzpatrick (investor relations), 425-415-2207 Lilly ICOS LLC (NYSE:LLY...
Eli Lilly and Company Rob Smith, 317-277-1302 www.lilly.com Gerhard Mayr, executive vice president, pharmaceutical operations, has announced that...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Subscribe to Ad free and enjoy an ad-free experience
Try Now
Keep the Ads